Hansa Biopharma AB (HNSA) — Working Capital to Net Assets Ratio
Hansa Biopharma AB (HNSA) has a Working Capital to Net Assets ratio of -35.6% as of June 2025. Working capital of Skr156.84 Million (current assets of Skr578.91 Million minus current liabilities of Skr422.07 Million) is measured against net assets of Skr-441.06 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hansa Biopharma AB balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hansa Biopharma AB Working Capital to Net Assets (2008–2024)
This chart shows how Hansa Biopharma AB's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the ratio stands at -35.6%, reflecting working capital of Skr156.84 Million against net assets of Skr-441.06 Million SEK. Check HNSA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hansa Biopharma AB (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hansa Biopharma AB from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Hansa Biopharma AB market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -55.9% | Skr329.74 Million | Skr-589.83 Million | Skr585.43 Million | Skr255.69 Million | ▲ +262.3 pp |
| 2023 | -318.2% | Skr534.16 Million | Skr-167.88 Million | Skr855.15 Million | Skr320.99 Million | ▼ -540.4 pp |
| 2022 | 222.3% | Skr1.34 Billion | Skr602.91 Million | Skr1.60 Billion | Skr264.71 Million | ▲ +120.5 pp |
| 2021 | 101.8% | Skr771.12 Million | Skr757.57 Million | Skr942.34 Million | Skr171.22 Million | ▼ -1.2 pp |
| 2020 | 103.0% | Skr1.28 Billion | Skr1.24 Billion | Skr1.39 Billion | Skr114.20 Million | ▲ +10.4 pp |
| 2019 | 92.6% | Skr521.20 Million | Skr562.82 Million | Skr615.74 Million | Skr94.54 Million | ▲ +0.3 pp |
| 2018 | 92.3% | Skr793.89 Million | Skr859.88 Million | Skr866.22 Million | Skr72.33 Million | ▲ +0.3 pp |
| 2017 | 92.1% | Skr580.58 Million | Skr630.66 Million | Skr624.18 Million | Skr43.60 Million | ▲ +10.5 pp |
| 2016 | 81.5% | Skr231.25 Million | Skr283.69 Million | Skr256.98 Million | Skr25.73 Million | ▲ +3.1 pp |
| 2015 | 78.4% | Skr165.78 Million | Skr211.53 Million | Skr178.30 Million | Skr12.51 Million | ▲ +63.2 pp |
| 2014 | 15.1% | Skr7.53 Million | Skr49.80 Million | Skr11.95 Million | Skr4.42 Million | ▲ +22.1 pp |
| 2013 | -6.9% | Skr-3.17 Million | Skr45.68 Million | Skr1.92 Million | Skr5.10 Million | ▼ -36.7 pp |
| 2012 | 29.8% | Skr18.82 Million | Skr63.24 Million | Skr21.38 Million | Skr2.56 Million | ▲ +39.2 pp |
| 2011 | -9.5% | Skr-3.28 Million | Skr34.71 Million | Skr2.91 Million | Skr6.19 Million | ▲ +3.6 pp |
| 2010 | -13.1% | Skr-4.21 Million | Skr32.17 Million | Skr1.42 Million | Skr5.64 Million | ▲ +0.6 pp |
| 2009 | -13.7% | Skr-3.43 Million | Skr24.92 Million | Skr1.80 Million | Skr5.23 Million | ▼ -22.5 pp |
| 2008 | 8.8% | Skr3.57 Million | Skr40.73 Million | Skr7.70 Million | Skr4.13 Million | — |